Skip to main content

Table 3 Overview of the expression of 26 markers based on categorical scoring: positive (≥ 5% positive tumor cells) vs. negative (< 5% positive tumor cells) cases

From: A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors

Marker

HGSC (n = 114)

LGSC (n = 97)

mSBT (n = 39)

HGSC vs. (LGSC + mSBT) p-value

HGSC vs. LGSC p-value

LGSC vs. mSBTp-value

ER

   

< 0.001

0.004

1.000

n positive

101 (89%)

93 (99%)

39 (100%)

   

n negative

13 (11%)

1 (1%)

0 (0%)

   

PR

   

< 0.001

0.005

< 0.001

n positive

36 (32%)

49 (51%)

32 (82%)

   

n negative

78 (68%)

48 (49%)

7 (18%)

   

PAX8

   

1.000

1.000

1.000

n positive

113 (99%)

95 (99%)

39 (100%)

   

n negative

1 (1%)

1 (1%)

0 (0%)

   

ARID1A

   

0.068

0.082

1.000

n positive

112 (98%)

88 (93%)

36 (95%)

   

n negative

2 (2%)

7 (7%)

2 (5%)

   

PTEN

   

< 0.001

< 0.001

1.000

n positive

96 (84%)

95 (99%)

38 (100%)

   

n negative

18 (16%)

1 (1%)

0 (0%)

   

HNF1B

   

0.801

0.538

0.294

n positive

34 (30%)

24 (26%)

12 (35%)

   

n negative

80 (70%)

69 (74%)

22 (65%)

   

Napsin A

   

NULL

NULL

NULL

n positive

0 (0%)

0 (0%)

0 (0%)

   

n negative

114 (100%)

96 (100%)

39 (100%)

   

CDX2

   

0.334

0.626

1.000

n positive

3 (3%)

1 (1%)

0 (0%)

   

n negative

111 (97%)

96 (99%)

39 (100%)

   

NTRK

   

0.458

1.000

NULL

n positive

1 (1%)

0 (0%)

0 (0%)

   

n negative

113 (99%)

96 (100%)

39 (100%)

   

MUC4

   

0.181

0.377

1.000

n positive

4 (4%)

1 (1%)

0 (0%)

   

n negative

110 (96%)

96 (99%)

39 (100%)

   

BRG1

   

1.000

0.459

1.000

n positive

114 (100%)

96 (99%)

39 (100%)

   

n negative

0 (0%)

1 (1%)

0 (0%)

   

PAX2

   

< 0.001

< 0.001

0.118

n positive

47 (41%)

64 (67%)

30 (81%)

   

n negative

67 (59%)

31 (33%)

7 (19%)

   

Mammaglobin

   

0.009

0.002

0.050

n positive

16 (14%)

2 (2%)

4 (11%)

   

n negative

98 (86%)

94 (98%)

33 (89%)

   

SATB2

   

0.475

0.728

0.557

n positive

5 (4%)

3 (3%)

0 (0%)

   

n negative

109 (96%)

94 (97%)

39 (100%)

   

RB1

   

 < 0.001

0.002

1.000

n positive

97 (86%)

90 (98%)

39 (100%)

   

n negative

16 (14%)

2 (2%)

0 (0%)

   

AMACR

   

0.588

0.461

0.508

n positive

8 (7%)

10 (10%)

2 (5%)

   

n negative

106 (93%)

86 (90%)

37 (95%)

   

TTF1

   

0.456

1.000

NULL

n positive

1 (1%)

0 (0%)

0 (0%)

   

n negative

113 (99%)

97 (100%)

39 (100%)

   

Cyclin E1

   

< 0.001

 < 0.001

0.743

n positive

108 (95%)

68 (73%)

26 (70%)

   

n negative

6 (5%)

25 (27%)

11 (30%)

   

Statmin

   

< 0.001

 < 0.001

0.431

n positive

110 (96%)

66 (70%)

24 (63%)

   

n negative

4 (4%)

28 (30%)

14 (37%)

   

BCOR

   

NULL

NULL

NULL

n positive

0 (0%)

0 (0%)

0 (0%)

   

n negative

114 (100%)

97 (100%)

39 (100%)

   

L1CAM

   

0.002

0.045

0.037

n positive

39 (34%)

20 (21%)

2 (5%)

   

n negative

75 (66%)

75 (79%)

35 (95%)

   

LMP2

   

0.002

0.009

NULL

n positive

106 (93%)

95 (100%)

38 (100%)

   

n negative

8 (7%)

0 (0%)

0 (0%)

   

CD44

   

 < 0.001

 < 0.001

1.000

n positive

30 (26%)

3 (3%)

1 (3%)

   

n negative

84 (74%)

90 (97%)

36 (97%)

   

Ki67

   

< 0.001

< 0.001

0.573

n positive

109 (96%)

16 (18%)

5 (14%)

   

n negative

5 (4%)

75 (82%)

32 (86%)

   

p16a

   

< 0.001

< 0.001

NULL

n positive

77 (68%)

0 (0%)

0 (0%)

   

n negative

37 (32%)

96 (100%)

38 (100%)

   

p53a

   

< 0.001

< 0.001

NULL

n positive

98 (91%)

0 (0%)

0 (0%)

   

n negative

10 (9%)

96 (100%)

38 (100%)

   
  1. ap53 protein expression was assessed as negative (“wild-type”) or positive (“aberrant type”). p16 was assessed as positive (block positivity) or negative (only focal or absent staining, see Methods section—Immunohistochemical analysis)
  2. p-values are based on Pearson chi-squared or Fisher Exact test, significant differences are indicated bold font
  3. HGSC High grade serous carcinoma, LGSC Low grade serous carcinoma, mSBT Micropapillary serous borderline tumor, NULL Values could not be generated